Analysis
Waiv's spin-off from Owkin is a testament to the growing power of AI in healthcare. This funding will fuel their mission to enhance cancer testing precision, potentially leading to earlier and more effective diagnoses. The promise of using AI to improve patient outcomes is incredibly exciting!
Key Takeaways
Reference / Citation
View Original"Paris-based Waiv, which uses AI to enable more precise testing of cancer, raised $33M after spinning out of AI diagnostics and drug discovery platform Owkin"